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Pregnant women constitute a promising sentinel group for 
continuous monitoring of malaria transmission. To identify 
antibody signatures of recent Plasmodium falciparum expo-
sure during pregnancy, we dissected IgG responses against 
VAR2CSA, the parasite antigen that mediates placental 
sequestration. We used a multiplex peptide-based suspen-
sion array in 2,354 samples from pregnant women from 
Mozambique, Benin, Kenya, Gabon, Tanzania, and Spain. 
Two VAR2CSA peptides of limited polymorphism were im-
munogenic and targeted by IgG responses readily boosted 
during infection and with estimated half-lives of <2 years. 
Seroprevalence against these peptides reflected declines 
and rebounds of transmission in southern Mozambique dur-
ing 2004–2012, reduced exposure associated with use of 
preventive measures during pregnancy, and local clusters 
of transmission that were missed by detection of P. falci-
parum infections. These data suggest that VAR2CSA se-
rology can provide a useful adjunct for the fine-scale esti-
mation of the malaria burden among pregnant women over 
time and space.
Agile malaria surveillance and response systems that can be sustained over time are needed for the optimal 
design of control programs (1,2). Rates of Plasmodium fal-
ciparum infection among pregnant women are sensitive to 
changes in transmission (3,4) and correlate well with infec-
tion in infants (5) and children (6,7). Thus, passive detection 
of malaria cases at maternal health care services constitutes 
a promising approach to providing contemporary data on the 
levels, and changes in levels, of malaria burden in the popu-
lation for successful malaria control and elimination (8).
After exposure to P. falciparum parasites that seques-
ter in the placenta (9), antibodies against VAR2CSA, a 
multidomain variant antigen of the P. falciparum erythro-
cyte membrane protein 1 family, develop in pregnant wom-
en (10). VAR2CSA is expressed on the surface of infected 
erythrocytes and mediates placental sequestration of para-
sites through binding to chondroitin sulfate A (11). Levels 
of antibodies against VAR2CSA are affected by variables 
that influence the risk for P. falciparum exposure (12–14) 
and mirror malaria trends during pregnancy (3). Moreover, 
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levels of VAR2CSA IgG at delivery correlate with the risk 
for malaria in the offspring (14), suggesting the value of 
these antibodies for pinpointing areas of high malaria trans-
mission (15). Because VAR2CSA antibodies persist after 
the infection is cleared (16), they can provide a sensitive 
adjunct for P. falciparum monitoring, especially in areas of 
low malaria endemicity, where the chances of detecting an-
tibodies are higher than those of detecting the parasite (17).
The utility of serosurveillance depends mainly on spe-
cific properties of the antigen, including immunogenicity, 
polymorphism, cross-reactivity, and longevity of the anti-
bodies. Because different VAR2CSA domains elicit IgG re-
sponses with varying magnitudes and dynamics (16,18,19), 
we hypothesized that short-lived antibodies against immu-
nogenic nonpolymorphic VAR2CSA epitopes would en-
able a fine-scale estimation of recent P. falciparum trans-
mission during pregnancy (17). We examined plasma from 
pregnant women living in areas in which P. falciparum 
transmission varied from high to low and absent (Benin, 
Gabon, Mozambique, Kenya, Tanzania, and Spain) against 
a quantitative suspension array containing VAR2CSA and 
general parasite antigens. We first selected IgG responses 
that were rapidly acquired after P. falciparum infection, 
did persist in circulation, and were sensitive to the level of 
parasite exposure in pregnant women from Mozambique 
and Spain. We then used the serologic assay to quantify 
the relationship of VAR2CSA antibody responses with 
P. falciparum infection as well as with temporal, spatial, 
and intervention-driven changes in malaria burden among 
pregnant women.
Methods
Study Sites, Population, and Procedures
We included in our study pregnant women who partici-
pated in 3 clinical trials of intermittent preventive treat-
ment during pregnancy (IPTp) during 2003–2005 in Mo-
zambique (NCT00209781) (20) and during 2010–2012 
in Mozambique, Benin, Gabon, Kenya, and Tanzania 
(NCT00811421) (21,22). Participants were recruited at 
their first antenatal visit, and all received a long-lasting 
insecticide-treated bed net. During 2003–2005, all received 
2 doses of sulfadoxine/pyrimethamine (20); during 2010–
2012, they received 2 doses of mefloquine or sulfadoxine/
pyrimethamine if they were not HIV infected (21) and 3 
doses of mefloquine or placebo plus daily cotrimoxazol 
prophylaxis if they were HIV infected (22). At delivery, 
tissue samples from the maternal side of the placenta, as 
well as 50 μL peripheral and placental dried blood spots 
(DBS), were collected. Peripheral and placental blood from 
pregnant women in Mozambique and Benin were also col-
lected into EDTA Vacutainer tubes (Becton Dickinson, 
https://www.bd.com) and centrifuged; plasma was stored 
at –20°C. From a subset of pregnant women in Mozam-
bique who delivered during 2011–2012, peripheral blood 
samples were also collected at the first antenatal visit and 
before administration of the second IPTp dose. We geo-
coded the households of women in Mozambique by using a 
global information system. Clinical malaria episodes were 
treated according to national guidelines at the time of the 
study (20–22). DBS and plasma samples were also col-
lected from 49 pregnant women never exposed to P. fal-
ciparum who delivered in 2010 at the Hospital Clinic of 
Barcelona (Barcelona, Spain).
The study was approved by the ethics committees from 
the Hospital Clínic of Barcelona, the Comité Consultatif de 
Déontologie et d’Éthique from the Institut de Recherche 
pour le Développement (Marseille, France), the Centers for 
Disease Control and Prevention (Atlanta, GA, USA), and 
national ethics review committees from each malaria-en-
demic country participating in the study. Written informed 
consent, which included permission to test for immune 
markers by using stored biological samples, was obtained 
from all participants.
Laboratory Determinations
At recruitment, we assessed HIV serostatus by using rap-
id diagnostic tests according to national guidelines and 
hemoglobin level at delivery by using following mobile 
devices on capillary blood samples: HemoCue (Danaher, 
http://www.hemocue.com), Hemocontrol (EKF Diagnos-
tics, http://www.ekfdiagnostics.com), and KX analyzer 
(Sysmex, http://www.sysmex.com). Thick and thin blood 
films and placental biopsy samples were checked for Plas-
modium spp. according to standard, quality-controlled pro-
cedures (3). We tested blood on filter paper for the presence 
of P. falciparum in duplicate by means of a real-time quan-
titative PCR (qPCR) targeting 18S ribosomal DNA (3).
Antibody Measurements
We measured IgG in plasma (Benin and Mozambique) or 
on DBS (Gabon, Kenya, and Tanzania) in appropriate con-
ditions for plasma elution (19) by using the xMAP tech-
nology and the Luminex 100/200 System (https://www.
luminexcorp.com) for 37% of pregnant women participat-
ing in the clinical trials with samples available. We con-
structed 2 multiplex suspension array panels (Appendix 1, 
https://wwwnc.cdc.gov/EID/article/25/10/18-1177-App1.
pdf) (19), 1 including P. falciparum recombinant proteins 
(VAR2CSA Duffy binding-like recombinant domains 
DBL3X, DBL5Ɛ, and DBL6Ɛ; apical membrane antigen 1 
[AMA1]; and 19-kDa fragment of the merozoite surface 
protein-1 [MSP119], from 3D7 strain) and 1 consisting of 
synthetic peptides (25 VAR2CSA peptides covering con-
served and semiconserved regions of VAR2CSA and a cir-
cumsporozoite peptide [pCSP]) (19). To assess unspecific 
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IgG recognition, we used bovine serum albumin in both 
arrays (19). Procedures for reconstitution of DBS and qual-
ity control, bead-based immunoassay, data normalization, 
and definition of seropositivity cutoffs are described in 
Appendix 1.
var2csa Sequencing and 3D Protein Modeling
We used DNA extracted from 50 DBS that were P. falci-
parum positive by qPCR for Sanger sequencing of var2csa 
PCR amplification products covering peptides of interest 
(Appendix 1). Sequence variability with respect to the pep-
tide included in the array was assessed after amino acid 
alignment, and a 3D model of the DBL1X-ID1 region was 
developed by using Chimera version 1.5.3 (https://www.
cgl.ucsf.edu; Appendix 1).
Definitions and Statistical Analyses
We included in the analysis pregnant women for whom all 
information was available for IPTp, date of delivery, HIV 
status, age, parity, and antibody responses. We classified 
women as primigravid (first pregnancy) or multigravid (>1 
previous pregnancy) and categorized age as <20, 20–24, or 
>25 years (13). Anemia was defined as hemoglobin level 
at delivery <11 mg/L. We compared proportions by using 
the Fisher exact test. We used univariate regression mod-
els to evaluate the association of log-transformed IgG lev-
els (linear) and seropositivity (logistic) with study periods 
(2004–2005 and 2010–2012) and country, P. falciparum 
infection, parity, anemia, and IPTp intervention, taking into 
account potential confounding variables (HIV and age) in 
multivariate models. We assessed the modification of the 
associations by HIV infection or parity by including inter-
action terms into the regression models. To control the false 
discovery rate in the selection of antigens, we computed 
adjusted p values (q-values) by using the Simes procedure 
(23). We used multilevel mixed-effect linear regression 
analysis to estimate half-life and time to double (T2×) IgG 
levels in the longitudinal cohort of pregnant women from 
Mozambique (Appendix 1). We identified spatial clusters 
of P. falciparum infection and seropositivity as well as the 
most likely hotspots by using the Ward hierarchical clus-
ter analysis and Kulldorff spatial scan method (Appendix 
1). We performed statistical analyses by using Stata/SE 
software version 12.0 (StataCorp, https://www.stata.com), 
R statistics software version 3.2.1 (https://www.r-project.
org), and Graphpad Prism version 6 (https://www.graph-
pad.com).
Results
Study Participants and P. falciparum Prevalence
Study participants consisted of 2,354 pregnant women (Ta-
ble; Appendix 1 Figure 2) recruited during 2004–2005 (n = 
146) and 2010–2012 (n = 2,208) in the context of IPTp clin-
ical trials (20–22). Among them, 993 were from Mozam-
bique, 854 from Benin, 131 from Gabon, 296 from Kenya, 
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Table. Participants in study of VAR2CSA serologic testing to detect Plasmodium falciparum transmission patterns, by country and  
HIV status* 
Variable 
HIV-uninfected, no. (%) 
 







n = 65 
Mozambique,† 
n = 485 
Benin,  
n = 854 
Gabon, 
n = 131 
Tanzania, 
n = 31 
Mozambique, 
n = 81 
Mozambique,† 
n = 362 
Kenya, 
n = 296 
Parity 
          
 Primigravid 17 (26) 
 




46 (13) 22 (7) 
 Multigravid 48 (74) 
 




316 (87) 274 (93) 
Age, y 
           
 <20 19 (29) 
 




41 (11) 15 (5) 
 20–24 17 (26) 
 




84 (23) 96 (32) 
 >25 29 (45) 
 




237 (65) 185 (62) 
IPTp 










 Mefloquine 0 
 




178 (49) 139 (47) 
 Placebo‡ 0 
 




184 (51) 157 (53) 
Microscopy§¶ 
           
 Positive 9 (14) 
 




8 (2) 15 (5) 
 Negative 56 (86) 
 




323 (98) 268 (95) 
qPCR¶# 
           
 Positive 16 (25) 
 




13 (4) 22 (8) 
 Negative 49 (75) 
 




314 (96) 251 (92) 
*IPTp, intermittent preventive treatment during pregnancy; qPCR, quantitative PCR. 
†40% (196/485) of HIV-uninfected and 12% (43/362) of HIV-infected participants were pregnant women with samples collected also at recruitment and 
second IPTp administration. 
‡All HIV-infected women who received placebo were also receiving cotrimoxazol prophylaxis. 
§Maternal microscopic infection defined by the presence of P. falciparum parasites in peripheral blood or in placenta on microscopic or histologic 
examination, respectively. 
¶Not determined: 179 microscopy and 196 qPCR. 
#Maternal qPCR-positive infection was defined by a positive result on qPCR testing in peripheral or placental blood. 
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31 from Tanzania, and 49 from Spain. The baseline charac-
teristics of the women selected for this trial were similar to 
those of the 6,216 women participating in the randomized 
clinical trials (Appendix 2 Table 1, https://wwwnc.cdc.gov/
EID/article/25/10/18-1177-App2.xlsx).
The study areas represented 5 sites in sub-Saharan 
Africa with different intensities of malaria transmission. 
Prevalence of P. falciparum infection detected by qPCR 
at delivery, in either peripheral or placental blood (aver-
aged for 2010–2012), among HIV-uninfected women was 
46% (332/725) in Benin, 10% (9/89) in Gabon, and 6% 
(28/452) in Mozambique and among HIV-infected women 
was 8% (22/273) in Kenya and 4% (13/327) in Mozam-
bique (Table). The prevalence of P. falciparum infection 
among pregnant women in Mozambique decreased from 
25% (37/146) in 2004–2005 to 2% (3/176) in 2010 and in-
creased to 6% (4/72) in 2012. A subset of 239 pregnant 
women from Mozambique recruited during 2011–2012 was 
followed during pregnancy; prevalence of P. falciparum 
infection detected by qPCR was 16% (38/239) at first ante-
natal visit (mean gestational age ± SD, 20.7 ± 5.45 weeks), 
3% (8/239) at the second IPTp administration (25.9 ± 4.98 
weeks), and 5% (13/239) at delivery (38.4 ± 2.26 weeks). 
P. falciparum infection was detected at unscheduled visits 
for 2% (5/239) of the women. Overall, P. falciparum in-
fection was detected at any of these time points for 21% 
(49/239) of the women.
P. falciparum–Specific Antibody Profiles and Parasite 
Exposure during Pregnancy
Mean antiparasite IgG levels in pregnant women from Mo-
zambique delivering from 2010 through 2012 were above 
levels against bovine serum albumin plus 3 SD and higher 
than IgG levels in pregnant women from Spain except for 
DBL6Ɛ and 3 of 25 VAR2CSA peptides (Figure 1, panel 
A; Appendix 2 Table 3). Five VAR2CSA peptides, DBL6Ɛ, 
and pCSP were recognized by IgG from >5% of the preg-
nant women from Spain who had never been exposed to 
P. falciparum (Figure 1, panel B), suggesting unspecific 
recognition; thus, these peptides were excluded from sub-
sequent analysis. To further narrow down the VAR2CSA 
peptide candidates, we compared IgG levels in pregnant 
women from Mozambique delivering in 2004–2005 and 
2010–2012, a period when P. falciparum prevalence as-
sessed by qPCR at delivery in peripheral or placental blood 
dropped from 25% to 5% (Figure 1, panel C) (3). This 
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Figure 1. Plasmodium 
falciparum VAR2CSA IgG 
in malaria-exposed and 
-nonexposed pregnant women. 
A) nMFI measured in pregnant 
women from Mozambique 
and Spain. Red dashed line 
represents the mean nMFI 
from bovine serum albumin 
+ 3 SDs. B) Seroprevalence 
among pregnant women from 
Spain (blue) and Mozambique 
(black). Asterisks indicate 
antigens recognized by pregnant 
women from Mozambique at 
levels above IgG against bovine 
serum albumin + 3 SDs and 
above levels in pregnant women 
from Spain (q-value <0.05 by 
Simes procedure) and those 
antigens poorly recognized by 
pregnant women from Spain 
(seroprevalence <5%). C, D) 
Prevalence of P. falciparum 
infection in peripheral and 
placental blood by quantitative 
PCR (C) and nMFIs (D) 
among pregnant women from 
Mozambique delivering in 2004–
2005 and 2010–2012. Red lines 
represent the geometric mean 
and T-bars the 95% CI. Asterisks 
indicate antigens recognized 
by IgG whose levels dropped between 2004 and 2012, as assessed by linear regression adjusted by intermittent preventive treatment 
during pregnancy, parity, age, and HIV status (q-value <0.05 by Simes procedure). nMFI, normalized median fluorescent intensity.
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decline in infection rates was mirrored by drops of IgG 
levels against 10 of the 18 previously selected VAR2CSA 
peptides (p1, p5, p8, p10, p12, p20, p27, p36, p38, p39) 
(Figure 1, panel D; Appendix 2 Table 4).
Acquisition and Decay of IgG Responses  
against VAR2CSA
We assessed the dynamics of IgG responses in a longitu-
dinal cohort of 239 pregnant women from Mozambique 
(Figure 2, panel A). At delivery, compared with uninfected 
women, the 49 (21%) women infected with P. falciparum 
during pregnancy had higher IgG levels against the 10 
down-selected peptides (Figure 2, panel B; Appendix 2 
Table 5). At delivery, seroprevalence rates for p1 (23%), 
p5 (26%), p8 (26%), and p39 (31%) antibodies were above 
the cumulative prevalence of P. falciparum infection dur-
ing pregnancy (Figure 2, panel C; Appendix 2 Table 5). No 
difference in IgG levels was observed between primigravid 
and multigravid women (Figure 2, panel D; Appendix 2 
Table 5). T2× after P. falciparum infection ranged from 0.45 
years (95% CI 0.31–0.80 years) for p5 to 1.07 years (95% 
CI 0.60–5.23 years) for p27 (Figure 2, panel E; Appendix 
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Figure 2. IgG responses during pregnancy against selected VAR2CSA antigens and polymorphism in target sequences in serologic 
study of Plasmodium falciparum in pregnant women. A) P. falciparum prevalence by quantitative PCR (qPCR) in 239 pregnant women 
from Mozambique at recruitment, second administration of IPTp, and delivery. Cumulative prevalence at delivery refers to peripheral 
or placental infection detected by microscopy, qPCR, or histology at any time point. B) Ratio of nMFIs at delivery in women from 
Mozambique infected during pregnancy compared with uninfected women. Error bars indicate 95% CIs. C) Seroprevalence at delivery, 
showing the cumulative prevalence of infection during pregnancy (red dashed line) and the prevalence at delivery by qPCR (light blue 
line). D) Ratio of nMFIs at delivery in multigravid compared with primigravid women, adjusted by IPTp, parity, age, and HIV status. 
Error bars indicate 95% CIs. E) IgG dynamics during pregnancy with estimates of time to double (T2x) and half-life (T1/2) obtained from 
linear mixed-effect regression model. Red points represent P. falciparum infection, dark gray lines the seropositivity cutoff, red lines the 
fitted-estimation, and dashed lines the 95% CI. F) Space-feeling representation of DBL1X-ID1 showing p5 (blue) and p8 (red). G) Logo 
representation of p5 and p8 sequences obtained from 50 P. falciparum isolates (20 from Mozambique, 10 from Benin, 10 from Gabon, 
and 10 from Kenya). IPTp, intermittent preventive treatment during pregnancy; nMFI, normalized median fluorescent intensity.
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2 Table 6). IgG half-life among seropositive women at 
recruitment without evidence of P. falciparum infection 
during follow-up ranged from 0.55 (95% CI 0.38–1.02) 
years for p8 to 3.66 (95% CI 0.98–∞) years for p1 (Fig-
ure 2, panel E; Appendix 2 Table 6). Among recombinant 
antigens, IgG DBL5Ɛ showed the lowest T2× (0.31 [95% 
CI 0.21–0.61] years) and half-life (0.66 [95% CI 0.42–
1.65] years), whereas AMA1 IgG showed the highest T2× 
(1.76 [95% CI 0.76–∞] years) and half-life (4.18 [95% CI 
1.86–∞] years).
Among the down-selected VAR2CSA peptides (p1, 
p5, p8, and p39), IgG against p5 (51 amino acids) and p8 
(48 amino acids) showed the lowest half-lives (0.55 [95% 
CI 0.38–1.02] years for p8; 1.33 [95% CI 0.65–∞] years for 
p5) and the largest increase in women exposed to P. falci-
parum during pregnancy compared with uninfected women 
(adjusted ratio [AR]p5 2.15 [95% CI 1.39–3.31] and ARp8 
2.17 [95% CI 1.46–3.23]; Figure 2, panel B; Appendix 1 
Figure 5; Appendix 2 Table 5). IgG levels and seropreva-
lence rates at delivery for p5 and p8 were higher among 
pregnant women with active or past malaria infection than 
among women with no parasite or pigment in the placenta, 
as assessed by histologic examination (Appendix 2 Table 
7). 3D modeling mapped both sequences on the exposed 
surface of DBL1X-ID1 region of VAR2CSA (Figure 2, 
panel F). Amino acid variability obtained from 50 P. falci-
parum isolates collected at study sites was 5% ± 2 SD for 
p5 sequences and 16% ± 5 SD for p8 sequences, compared 
with the consensus peptide sequence included in the array 
(Figure 2, panel G; Appendix 1 Figures 3, 4).
Performance of Selected VAR2CSA Peptides  
for Assessing Spatial and Temporal Differences  
in P. falciparum Exposure
In pregnant women from Mozambique at delivery, p5 
and p8 seroprevalence rates, as well as the composite of 
both (p5+8), decreased from 2004–2005 to 2010 (adjusted 
odds ratio [AOR]p5+8 0.27 [95% CI 0.11–0.68]), followed 
by an increase from 2010 to 2012 (AORp5+8 2.49 [95% CI 
1.34–4.61]; Figure 3, panel A; Appendix 2 Table 8). This 
decrease and subsequent increase mirrored P. falciparum 
prevalence by qPCR. HIV infection and parity did not 
modify the associations observed (p value for interaction 
>0.05 for all cases; Appendix 2 Table 8). Similar to P. fal-
ciparum prevalence determined by qPCR, seroprevalence 
rates were the highest in HIV-uninfected women from Be-
nin, followed by those from Gabon (AORp5+8 0.31 [95% CI 
0.21–0.47]) and Mozambique (AORp5+8 0.21 [95% CI 0.16–
0.28]; Figure 3, panel B; Appendix 2 Table 9). At delivery, 
pregnant women living in an area from Tanzania where no 
P. falciparum infection was detected by qPCR were sero-
negative against p5, p8, and p5+8 antibodies; 42% were 
seropositive against AMA1 and 48% were seropositive 
against MSP119 antibodies (Figure 3, panel B). Among 
HIV-infected women, seroprevalence rates for p8 and p5+8 
were lower in Mozambique than in Kenya (AORp5+8 0.58 
[95% CI 0.38–0.88]; Figure 3, panel C; Appendix 2 Table 
9). p5 and p5+8 seroprevalence rates were higher among 
anemic than among nonanemic women (AORp5+8 1.26 
[95% CI 1.03–1.55]; Figure 3, panel D; Appendix 2 Table 
10). Seroprevalence rates were lower among HIV-uninfect-
ed women who received IPTp with mefloquine than among 
those who received sulfadoxine/pyrimethamine (AORp5+8 
0.74 [95% CI 0.59–0.94]; Figure 3, panel E; Appendix 2 
Table 11). Seroprevalence rates among HIV-infected wom-
en were lower among those who received mefloquine than 
among those who received placebo, although differences 
were not significant (AORp5+8 0.76 [95% CI 0.50–1.15]; 
Figure 3, panel F; Appendix 2 Table 11).
Geographic Patterns of P. falciparum Transmission  
through VAR2CSA Serologic Testing
Spatial geocoordinates were available for 698 pregnant 
women from Mozambique residing in Manhiça District 
(southern Mozambique). Geographic areas experiencing 
significantly higher seroprevalence rates than would be ex-
pected by chance were observed for p5 (radius 2.82 km; 
p = 0.024) and p5+8 (radius 1.06 km; p = 0.049) but not 
for MSP119 and AMA1 (Figure 4; Appendix 2 Table 12). 
The distribution of HIV infection, parity, age, and IPTp 
was similar among women inside and outside the serologic 
hotspot (p>0.05; Appendix 2 Table 12).
Discussion
Routine P. falciparum testing of easily accessible pregnant 
women at maternal healthcare services has the potential 
to offer a rapid, consistent, and cost-effective method for 
evaluating the malaria burden in different communities and 
tracking progress of interventions. IgGs against 2 VAR2C-
SA peptides, selected according to their ability to maximize 
the information about recent P. falciparum exposure dur-
ing pregnancy, reflected differences in malaria burden over 
time and space in multiple settings in Africa and changes in 
parasite rates associated with the use of different preventive 
regimens. Overall, our results indicate that in areas with 
well-attended maternal healthcare services, this pregnancy-
specific serologic test may serve as a useful sentinel sur-
veillance tool for flagging changes in malaria burden and 
progress in the path toward elimination.
p5 (51 amino acids) is localized in the DBL1X domain 
and p8 (48 amino acids) in the ID1 region of VAR2CSA. 
Limited diversity (5%) of p5 sequence was observed in P. 
falciparum isolates from a variety of regions of Africa, in 
accordance with estimates from previous studies for the 
DBL1X domain (24). p8 corresponds to a more diverse 
(16%) variant of the ID1 region in VAR2CSA (25). Both 
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peptides are exposed on the DBL1X-ID1 N terminal region 
of VAR2CSA (18,26) and recognized by IgG from malar-
ia-exposed pregnant women at levels higher than those of 
pregnant women from Spain and men from Mozambique 
(19). IgG responses against both VAR2CSA peptides in-
creased with P. falciparum infection during pregnancy. 
Moreover, higher risk for anemia among p5 and p5+8 sero-
responders support these antibodies as markers of recent in-
fection, which adversely affects the women’s health (3). In 
contrast to the slow decay of IgG responses against AMA1, 
the half-life of IgG against p5 and p8 was <2 years, the 
average time reported in Mozambique for a second preg-
nancy to occur (27). The short half-life of p5 and p8 IgG, 
together with the similar IgG levels in multigravid and pri-
migravid women, suggests that antibodies acquired during 
one pregnancy are not maintained over multiple pregnan-
cies; thus, antibodies can be used as a reliable indicator of 
recent exposure for pregnant women, regardless of parity.
Seroprevalence rates for p5, p8, and the composite of 
both peptides (p5+8) mirrored trends in P. falciparum preva-
lence among pregnant women from Mozambique deliver-
ing during 2004–2012 (3), a temporal pattern that was also 
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Figure 3. IgG seroprevalence 
against VAR2CSA selected 
antigens according to study 
period, country, anemia status 
and intermittent preventive 
treatment group in serologic 
study of Plasmodium falciparum 
in pregnant women. A) Pregnant 
women from Mozambique 
delivering during different 
periods. B) HIV-uninfected 
pregnant women from Benin, 
Gabon, Mozambique, and 
Tanzania. C) HIV-infected 
pregnant women from 
Kenya and Mozambique. D) 
Nonanemic (NA) and anemic 
(A) pregnant women. E) HIV-
uninfected pregnant women 
receiving mefloquine (MQ) or 
sulfadoxine/pyrimethamine 
(SP) as intermittent preventive 
treatment during pregnancy 
(IPTp). F) HIV-infected 
pregnant women receiving 
MQ or placebo (PL) as IPTp. 
Maternal microscopic infection 
was defined by the presence 
of P. falciparum parasites in 
peripheral blood or in placenta 
on microscopic or histologic 
examination, respectively. 
Maternal quantitative PCR 
(qPCR)–positive infection was 
defined by a positive result on 
qPCR of peripheral or placental 
blood. P-values were obtained 
from multivariate regression 
models adjusted for HIV, parity, 
age, IPTp, and country when 
applicable. T-bars represent 95% 
CIs. *Crude p<0.05; **adjusted 
p<0.05. B, Benin; G, Gabon; K, 
Kenya; M, Mozambique; OM, 
optical microscopy; T, Tanzania.
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observed for PfPR2–10 (28). Trends were similar among HIV-
uninfected and infected women, suggesting that impairment 
of P. falciparum–specific antibody responses driven by vi-
ral infection (29) may not affect short-lived IgG responses 
against p5 and p8. Seroprevalence also reflected the bur-
den of malaria among pregnant women residing in a vari-
ety of settings in Africa, as well as reductions in infection 
rates resulting from the use of mefloquine as IPTp among 
HIV-uninfected women (21). Similar trends, although not 
statistically significant, were observed among HIV-infect-
ed women receiving cotrimoxazol prophylaxis alone or in 
combination with mefloquine (22), possibly because of the 
longer duration of protection provided by 3 IPTp doses in 
HIV-infected women compared with the 2 doses in HIV-
uninfected women. We also found that pregnant women liv-
ing in an area from Tanzania where no P. falciparum infec-
tion was detected by qPCR as well as pregnant women from 
Spain never exposed to malaria were seronegative against p5 
and p8, suggesting that pregnancy-specific serology might 
be used to confirm the eventual interruption of transmission.
Geographic distribution of pregnant women from 
Mozambique who were seropositive against p5 and p5+8 
revealed a serologic hotspot in an area close to the river 
and sugar cane plantations, where the density of anopheline 
mosquitoes can be expected to be higher. In contrast, anti-
bodies against MSP119 and AMA1 were not able to identify 
these malaria transmission patterns because of saturation 
of antibody responses after lifelong exposure to P. falci-
parum. These results support the value of using VAR2CSA 
serologic testing to amplify signals of recent exposure and 
suggest its potential to trigger targeted interventions to per-
sons living in close proximity to passively detected sero-
positive pregnant women.
Our study has several limitations. First, the peptide ar-
ray we used may have missed some conformational nonlin-
ear epitopes. Second, different transmission dynamics and 
host genetic factors may affect the acquisition and decay of 
antibodies (16). Third, steeper decay of antibodies may be 
observed out of pregnancy when infecting parasites express 
non-VAR2CSA variants. Fourth, the reduction of data from 
median fluorescence intensity to seroprevalence to simplify 
the serologic information of the assay may reduce the depth 
of serologic information. Developing alternative mathemat-
ical models that use antibody levels (30) may increase the 
sensitivity to detect temporal and spatial changes in malar-
ia transmission. Fifth, small numbers of pregnant women 
from malaria-free areas in Tanzania and Spain limit the 
generalizability of our data to support pregnancy-specific 
serologic testing as a tool to confirm interruption of trans-
mission. Last, antibody assessments in this study were con-
ducted mainly at delivery; further studies should assess the 
performance of this testing at antenatal visits or soon after 
delivery (i.e., during infant immunization). Future research 
is needed to describe the relationship between pregnancy-
specific serologic testing and malaria transmission in the 
general population and its value for confirming interruption 
of malaria transmission and providing early signals of P. 
falciparum resurgence after local elimination.
In summary, this study shows that IgG against 2 
VAR2CSA peptides from the DBL1X-ID1 domain reveal 
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Figure 4. Geographic patterns 
of Plasmodium falciparum 
infection and IgG seropositivity 
in pregnant women living 
in southern Mozambique. 
Geographic distribution of 
seropositive pregnant women 
(HIV-uninfected and HIV-
infected) living in Manhiça 
District, Mozambique, who 
delivered during 2010–2012 
and for whom microscopy, 
quantitative PCR (qPCR), and 
spatial geocoordinates were 
available. Distribution shows 
pregnant women with and 
without P. falciparum infection 
at delivery, either in peripheral 
or in placental blood, detected 
by microscopy or histology (A) 
or qPCR (B), as well as AMA1 
(C), MSP119 (D), p5 (E), p8 
(F), and p5+8 (G) seropositive 
and seronegative pregnant women at delivery. Grey dots indicate seronegative women, blue dots indicate seropositive women, red 
dots indicate seropositive women selected by the hotspot cluster algorithm; red circles indicate the most likely hotspot (continuous 
line p<0.05, dashed line p>0.05). Maps were generated by using OpenStreetMap (https://www.openstreetmap.org). Hotspot NE, not 
estimated because of low/high prevalence of seropresponders.
VAR2CSA Serology and P. falciparum Transmission 
temporal and spatial differences in malaria burden among 
pregnant women and reductions in exposure associated 
with the use of preventive measures during pregnancy. 
These antibodies enable the identification of local clusters 
of transmission that are missed by detection of P. falci-
parum infections. Our results suggest that inferring recent 
exposure through VAR2CSA serologic testing would am-
plify signals of ongoing malaria transmission and increase 
the power to detect changes, either natural or driven by 
deliberate efforts, as well as malaria hotspots, among preg-
nant women (2). Moreover, peptides such as p1 targeted 
by long-lasting IgG responses may be useful for capturing 
past changes in transmission by sampling women of child-
bearing age and relating seroprevalence with the number 
and timing of previous pregnancies. Operationally suitable 
serologic tests (31) capable of detecting antibodies against 
VAR2CSA synthetic peptides may be used in programmat-
ic environments to stratify areas based on malaria burden, 
measure the effects of interventions, and document year-to-
year changes in transmission. 
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